Enteroviral Meningoencephalitis after Anti-CD20 (Rituximab) Treatment

Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2003-02, Vol.36 (3), p.e47-e49
Main Authors: Quartier, Pierre, Tournilhac, Olivier, Archimbaud, Christine, Lazaro, Leila, Chaleteix, Carine, Millet, Pascale, Peigue-Lafeuille, Hélène, Blanche, Stéphane, Fischer, Alain, Casanova, Jean-Laurent, Travade, Philippe, Tardieu, Marc
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20 - immunology
Antineoplastic Agents - adverse effects
Child
Humans
Meningoencephalitis - chemically induced
Middle Aged
Rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.
ISSN:1058-4838
1537-6591
DOI:10.1086/345746